Loading...
Mereo BioPharma Group plc
MREO•NASDAQ
Healthcare
Biotechnology
$-0.01(-3.03%)
U.S. Market opens in 37h 6mMereo BioPharma Group plc (MREO) AI-Powered Stock Analysis
See how Mereo BioPharma Group plc scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMereo BioPharma Group plc (MREO) Stock Overall Grade
Mereo BioPharma Group plc’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Mereo BioPharma Group plc's overall stock rating.
Forecast
C+Score
52/100Financial Growth
AScore
80/100Fundamental Growth
C+Score
51/100Key Ratios
C+Score
55/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
BScore
69/100Mereo BioPharma Group plc (MREO) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (69/100,B) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Mereo BioPharma Group plc stock grade, including financials, comparisons, and forecasts.